KING ABDULLAH INTERNATIONAL MEDICAL RESEARCH CENTER

🇸🇦Saudi Arabia

Country: 🇸🇦Saudi Arabia

Ownership: -

Employees: -

Market Cap: -

Website: http://kaimrc.med.sa/

Clinical Trials

Neutrolin Versus Heparin for Locking Hemodialysis Catheters

Not Applicable

Conditions: Hemodialysis Catheter Infection
Catheter Thrombosis

Interventions: Device: Neutrolin
Drug: Heparin

First Posted Date: 2018-02-07

Last Posted Date: 2019-03-05

Lead Sponsor: King Abdullah International Medical Research Center

Target Recruit Count: 192

Registration Number: NCT03425448

Drug Coated Balloons vs Plain Balloons for the Management of Dysfunctional Dialysis Fistula

Not Applicable

Terminated

Conditions: Dysfunctional Dialysis Arteriovenous Fistula

Interventions: Device: Vessel preparation with angioplasty
Device: Plain balloon angioplasty
Device: Drug coated balloon angioplasty

First Posted Date: 2017-06-16

Last Posted Date: 2019-05-01

Lead Sponsor: King Abdullah International Medical Research Center

Target Recruit Count: 23

Registration Number: NCT03189667

Locations: 🇸🇦
King ABdulaziz Medical City, Riyadh, Saudi Arabia

To Study the Effect of Adding on Pegylated Interferon (PEG-INF) Therapy for Patients Diagnosed With Chronic Hepatitis B

Phase 4

Conditions: Hepatitis B

Interventions: Drug: PEG-IFN & Nucleos(t)tide analogues
Drug: Nucleos(t)tide analogues

First Posted Date: 2016-12-06

Last Posted Date: 2018-03-09

Lead Sponsor: King Abdullah International Medical Research Center

Target Recruit Count: 214

Registration Number: NCT02982837

Locations: 🇸🇦
King Abdulaziz Medical City, Riyadh, Saudi Arabia
🇸🇦
King Abdulaziz Hospital, Jeddah, Saudi Arabia

Daily Ginger Drinking and Platelet Function

Not Applicable

Completed

Conditions: Platelets Dysfunction
Hematological Diseases

Interventions: Dietary Supplement: Ginger drink

First Posted Date: 2016-08-30

Last Posted Date: 2016-08-30

Lead Sponsor: King Abdullah International Medical Research Center

Target Recruit Count: 40

Registration Number: NCT02882776

Locations: 🇸🇦
King Abdulaziz Medical City - National Guard Hospital, Riyadh, Central, Saudi Arabia

MERS-CoV Infection tReated With A Combination of Lopinavir /Ritonavir and Interferon Beta-1b

Phase 2

Completed

Conditions: Middle East Respiratory Syndrome Coronavirus (MERS-CoV)

Interventions: Drug: Combination of Lopinavir /Ritonavir and Interferon beta-1b
Drug: Placebo

First Posted Date: 2016-07-27

Last Posted Date: 2020-05-20

Lead Sponsor: King Abdullah International Medical Research Center

Target Recruit Count: 95

Registration Number: NCT02845843

Locations: 🇸🇦
Intensive Care Unit, King Abdulaziz Medical City, National Guard Health Affairs, Riyadh, Saudi Arabia
🇸🇦
King Abdullah International Medical Research Center, Riyadh, Saudi Arabia

Carglumic Acid in Methylmalonic Acidemia and Propionic Acidemia

Phase 3

Completed

Conditions: Propionic Acidemia
Methylmalonic Acidemia

Interventions: Drug: Carglumic Acid

First Posted Date: 2015-04-27

Last Posted Date: 2019-04-25

Lead Sponsor: King Abdullah International Medical Research Center

Target Recruit Count: 33

Registration Number: NCT02426775

Locations: 🇸🇦
King Fahad Medical City, Riyadh, Saudi Arabia
🇸🇦
King Abdullah Specialist Children Hospital, King Abdulaziz Medical City, Riyadh, Saudi Arabia

Quadripolar Leads for the Management of Heart Failure Patients in the Middle East

Phase 4

Conditions: Heart Failure

Interventions: Other: Anatomical optimization of device and leads
Other: Electrical optimization by RVLV Conduction Time with VectSelect
Device: Implanted device and lead (Cardiac Resynchronization Therapy Defibrillator (CRT-D) device and SJM Quadripolar lead system)

First Posted Date: 2014-07-21

Last Posted Date: 2014-07-21

Lead Sponsor: King Abdullah International Medical Research Center

Target Recruit Count: 389

Registration Number: NCT02195843

Anti-MERS-CoV Convalescent Plasma Therapy

Phase 2

Withdrawn

Conditions: Respiratory Distress Syndrome (& [Hyaline Membrane Disease])

Interventions: Biological: Convalescent plasma

First Posted Date: 2014-07-15

Last Posted Date: 2018-11-21

Lead Sponsor: King Abdullah International Medical Research Center

Registration Number: NCT02190799

Locations: 🇸🇦
Intensive Care Unit, King Abdulaziz Medical City, Riyadh,, Saudi Arabia

Efficacy and Safety Assessment of NIlotinib in CML Patients With Suboptimal Response on Imatinib Therapy

Phase 4

Terminated

Conditions: Myeloid Leukemia, Chronic

Interventions: Drug: Nilotinib 300 mg.

First Posted Date: 2014-03-13

Last Posted Date: 2017-03-07

Lead Sponsor: King Abdullah International Medical Research Center

Target Recruit Count: 98

Registration Number: NCT02086487

Locations: 🇸🇦
King Fahad specialist Hospital, Dammam, Eastern, Saudi Arabia
🇸🇦
National Guard Hospital, Riyadh, Central, Saudi Arabia

Effectiveness of Different Interventions for Implementing Surviving Sepsis Campaign (SSC) Guidelines on Compliance and Mortality: Systematic Review and Meta-analysis

Conditions: Sepsis
Septic
Septicemia

First Posted Date: 2014-02-21

Last Posted Date: 2014-02-21

Lead Sponsor: King Abdullah International Medical Research Center

Target Recruit Count: 30

Registration Number: NCT02069028

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy